Effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: A prospective single-center, open-label pilot study

Arthritis and Rheumatism

Volumn 64, Issue 12, 2012, Pages 4072-4077

  Saggar, Rajeev ^a   Khanna, D ^b   Shapiro, S ^c   Furst, D E ^c   Maranian, P ^c   Clements, P ^c   Abtin, F ^c   Dua, Shiv ^d   Belperio, J ^c   Saggar, Rajan ^c  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANTIHYPERTENSIVE AGENT; PHENYLPROPIONIC ACID DERIVATIVE; PYRIDAZINE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CLINICAL ARTICLE; CONSTIPATION; DIASTOLIC DYSFUNCTION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG HYPERSENSITIVITY; ERGOMETRY; EXERCISE; EXERCISE INDUCED PULMONARY HYPERTENSION; EYE SWELLING; FECES INCONTINENCE; FEMALE; FORCED VITAL CAPACITY; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE CONTRACTION; HUMAN; LEG EDEMA; LIVER FUNCTION TEST; LUNG ALVEOLUS CELL CARCINOMA; LUNG ARTERY PRESSURE; LUNG FIBROSIS; LUNG VASCULAR RESISTANCE; MALE; MUSCLE DISEASE; NOSE OBSTRUCTION; OXYGEN SATURATION; PAIN; PARESTHESIA; PERICARDIAL EFFUSION; PILOT STUDY; PRIORITY JOURNAL; PULLED BACK MUSCLE; PULMONARY HYPERTENSION; QUALITY OF LIFE; REST; SIDE EFFECT; SKIN PRURITUS; SUPINE POSITION; SYSTEMIC SCLEROSIS; TINEA CORPORIS; TREATMENT DURATION; WALKING; AGED; BLOOD PRESSURE; CLINICAL TRIAL; DOSE RESPONSE; ENDURANCE; HEMODYNAMICS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIAC OUTPUT; DOSE-RESPONSE RELATIONSHIP, DRUG; EXERCISE; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHENYLPROPIONATES; PHYSICAL ENDURANCE; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRIDAZINES; QUALITY OF LIFE; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 84870322299     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34614     Document Type: Article

References (19)

1. Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassounet PM, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60: 569-77.
2. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 252-60.
3. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-7.
4. Saggar R, Khanna D, Furst DE, Shapiro S, Maranian P, Belperio JA, et al. Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities. Arthritis Rheum 2010; 62: 3741-50.
5. Kovacs G, Maier R, Aberer E, Brodmann M, Scheidl S, Troster N, et al. Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. Am J Respir Crit Care Med 2009; 180: 881-6.
6. Proudman SM, Stevens WM, Sahhar J, Celermajer D,. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007; 37: 485-94. (Pubitemid 46855082)
7. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
8. Mukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois, RM, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004; 43: 461-6. (Pubitemid 38489363)
9. Steen V, Medsger TA Jr., Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-22. (Pubitemid 36278021)
10. Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr., Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35: 765-70.
11. Zisman DA, Karlamangla AS, Ross DJ, Keane MP, Belperio JA, Saggar R, et al. High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2007; 132: 773-9.
12. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, et al. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum 2007; 56: 1676-84. (Pubitemid 46764099)
13. Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006; 65: 1325-9. (Pubitemid 44620441)
14. Gomberg-Maitland M, Thenappan T, Rizvi K, Chandra S, Meads DM, McKenna SP,. United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant 2008; 27: 124-30.
15. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 Suppl: S55-66.
16. Steen V, Chou M, Shanmugam V, Mathias M, Kuru T, Morrissey R,. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest 2008; 134: 146-51. (Pubitemid 352008776)
17. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-619.
18. Tolle JJ, Waxman AB, Van Horn TL, Pappagianopoulos PP, Systrom DM,. Exercise-induced pulmonary arterial hypertension. Circulation 2008; 118: 2183-9.
19. Kovacs G, Berghold A, Scheidl S, Olschewski H,. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34: 888-94.